[go: up one dir, main page]

AR128627A1 - Agente terapéutico para enfermedades neurodegenerativas - Google Patents

Agente terapéutico para enfermedades neurodegenerativas

Info

Publication number
AR128627A1
AR128627A1 ARP230100469A ARP230100469A AR128627A1 AR 128627 A1 AR128627 A1 AR 128627A1 AR P230100469 A ARP230100469 A AR P230100469A AR P230100469 A ARP230100469 A AR P230100469A AR 128627 A1 AR128627 A1 AR 128627A1
Authority
AR
Argentina
Prior art keywords
fragment
derivative
gpnmb
gpnmb antibody
nucleic acid
Prior art date
Application number
ARP230100469A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Takami Tomiyama
Tomohiro Umeda
Original Assignee
Teijin Pharma Ltd
Univ Osaka Public Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Univ Osaka Public Corp filed Critical Teijin Pharma Ltd
Publication of AR128627A1 publication Critical patent/AR128627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La invención proporciona un medio para regular específicamente la microglía con mal funcionamiento y también proporciona una droga farmacéutica sobre la base de un nuevo mecanismo de acción utilizando dichos medios. El anticuerpo anti-gpNMB o su fragmento o un derivado del mismo según la invención se une específicamente a al menos un sitio en una región de un dominio tipo PMEL-CAF (tipo fragmento amiloide del núcleo de PMEL) a un dominio PKD de gpNMB humana (glicoproteína proteína B de melanoma no metastásico). Reivindicación 18: Una molécula de ácido nucleico que comprende una secuencia de polinucleótidos que codifica un anticuerpo anti-gpNMB o su fragmento o un derivado del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 17. Reivindicación 19: Un vector de clonación o vector de expresión que tiene al menos una molécula de ácido nucleico de acuerdo con la reivindicación 18. Reivindicación 20: Una célula recombinante transformada con un vector de acuerdo con la reivindicación 19. Reivindicación 21: Un método para producir un anticuerpo anti-gpNMB o su fragmento o un derivado del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 17, que comprende cultivar una célula recombinante de acuerdo con la reivindicación 20. Reivindicación 23: Una vacuna que tiene una actividad para estimular la producción de un anticuerpo anti-gpNMB o su fragmento o un derivado del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 17, que comprende un polipéptido que tiene la misma secuencia de aminoácidos que una región que contiene los residuos de aminoácidos D287 y/o H301 y/o una región que contiene los residuos de aminoácidos R214 y/o R215 de gpNMB humana que tiene la secuencia de aminoácidos definida en SEQ ID Nº 209. Reivindicación 24: Una composición farmacéutica que comprende, como ingrediente activo, uno o más seleccionados del grupo que consiste en un anticuerpo anti-gpNMB o su fragmento o un derivado del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 17, una molécula de ácido nucleico de acuerdo con la reivindicación 18, un vector de acuerdo con la reivindicación 19, y una célula recombinante de acuerdo con la reivindicación 20.
ARP230100469A 2022-02-28 2023-02-27 Agente terapéutico para enfermedades neurodegenerativas AR128627A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022029825 2022-02-28
JP2022075095 2022-04-28

Publications (1)

Publication Number Publication Date
AR128627A1 true AR128627A1 (es) 2024-05-29

Family

ID=87766263

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100469A AR128627A1 (es) 2022-02-28 2023-02-27 Agente terapéutico para enfermedades neurodegenerativas

Country Status (12)

Country Link
US (1) US20250171557A1 (es)
EP (1) EP4488292A1 (es)
JP (1) JPWO2023163187A1 (es)
KR (1) KR20240139072A (es)
AR (1) AR128627A1 (es)
AU (1) AU2023226313A1 (es)
CA (1) CA3244753A1 (es)
CO (1) CO2024010819A2 (es)
IL (1) IL314246A (es)
MX (1) MX2024010163A (es)
TW (1) TW202400643A (es)
WO (1) WO2023163187A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2025047850A1 (ja) * 2023-08-30 2025-03-06 帝人ファーマ株式会社 神経変性疾患の治療剤
WO2025166040A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6334496U (es) 1986-08-21 1988-03-05
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DK1827492T3 (da) 2004-11-30 2010-11-22 Curagen Corp Antistoffer rettet mod GPNMB og anvendelser deraf
CA2627890A1 (en) 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
KR102106821B1 (ko) * 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
US20220267374A1 (en) 2019-07-29 2022-08-25 Juntendo Educational Foundation Immunity inducer and pharmaceutical composition for preventing or treating aging-related diseases

Also Published As

Publication number Publication date
US20250171557A1 (en) 2025-05-29
KR20240139072A (ko) 2024-09-20
CA3244753A1 (en) 2025-06-13
EP4488292A1 (en) 2025-01-08
WO2023163187A1 (ja) 2023-08-31
CO2024010819A2 (es) 2024-08-20
TW202400643A (zh) 2024-01-01
IL314246A (en) 2024-09-01
AU2023226313A1 (en) 2024-08-01
JPWO2023163187A1 (es) 2023-08-31
MX2024010163A (es) 2024-08-27
EP4488292A9 (en) 2025-06-18

Similar Documents

Publication Publication Date Title
AR128627A1 (es) Agente terapéutico para enfermedades neurodegenerativas
PE20220283A1 (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento
MX2022004345A (es) Construcciones de igf2 variantes.
PE20231949A1 (es) VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112022023288A2 (pt) Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos
MX2024015050A (es) L-asparaginasa modificada
JP2018506542A (ja) 核酸製品及びその投与方法
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
CL2022000376A1 (es) Composiciones, formulaciones y producción y purificación de interleucinas
PE20220930A1 (es) Composiciones utiles en el tratamiento de leucodistrofia metacromatica
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
CL2021001280A1 (es) Dendrímero terapéutico
MX2022001717A (es) Aplicacion de polipeptido o derivado del mismo.
CO2023000048A2 (es) Conjugados de citoquina
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
AR133688A1 (es) Agente terapéutico para enfermedades neurodegenerativas
JP2017525675A5 (es)
ES2143408B1 (es) Promotor y construcciones para expresion de proteinas recombinantes en hongos filamentosos.
ES2698615T3 (es) Inhibición de la síntesis de la proteína betaAPP o de la actividad del péptido Abeta en los plexos coroideos
AR122445A1 (es) Elementos reguladores de plantas y sus usos
PE20212072A1 (es) Composiciones utiles en el tratamiento de la enfermedad de krabbe
CO2023010473A2 (es) Composiciones y métodos de terapia celular para modular la señalización del tgf-b
AR124310A1 (es) INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO
AR133967A1 (es) Región 3’ no traducida no natural y su uso
US20250127880A1 (en) Fusion polypeptide